scroll to top of page

Clinical trials are research studies designed to discover new ways to treat different cancers, and directly impact the number of new therapies and treatments available to fight cancer. Today’s trials are tomorrow’s standard of cancer care.

Thompson was the first to bring cancer clinical trials to East Tennessee more than 25 years ago. Today, Thompson’s clinical trials department is under the leadership of David Chism, MD and Susan Owenby, RN, CCRP, System Director of Clinical Research. Our oncologists are certified to participate in clinical trials and work with multiple cancer research groups to bring innovative treatments to East Tennessee. In addition, we partner with pharmaceutical companies to give our patients access to new treatments not otherwise available. We offer clinical trials because they often lead to better ways to diagnose, treat, and prevent cancer, allowing people to live healthier and longer lives. Ask your doctor if a clinical trial might be right for you.

Thompson Cancer Survival Center offers clinical trials at the following Thompson Oncology Group locations:

  • Blount 
  • Downtown Knoxville
  • Lenoir City 
  • Oak Ridge 
  • West Knoxville

Bladder

Protocol Number NCT Number Title Principal Investigator
IMMU 132-13

NCT04527991

A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Subjects With Metastatic or Locally Advanced Unresectable Urothelial Cancer David Chism, MD

Breast

Protocol Number NCT Number Title Principal Investigator

WO42633  (Astefania)

NCT04873362

A Phase III, Randomized, Double-Blind, Placebo-Controlled clinical trial to evaluate the efficacy and safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for HER2-Positive Breast Cancer at high risk of recurrence following preoperative therapy

David Chism, MD

 

D8534C00001   (Serena-6)

 

NCT04964934

A Phase III, Double-blind, Randomised Study to
Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor (Palbociclib or Abemaciclib) vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole) + CDK4/6
Inhibitor in HR+/HER2- MBC Patients with Detectable ESR1 Mutation Without Disease Progression During 1L Treatment with
Aromatase Inhibitor + CDK4/6 Inhibitor

David Chism, MD

ML43171

NCT0536340

A Phase III, randomized, open-label, multicenter study evaluating the efficacy and safety of Giredestrant plus Everolimus compared with Exemestane plus Everolimus in patients with estrogen receptor-positive, her2- negative, locally advanced or metastatic breast cancer

David Chism, MD


Esophageal

Protocol Number NCT Number Title Principal Investigator

MK3475-975

 

NCT04210115

 

A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975)

David Chism, MD

Gastrointestinal

Protocol Number NCT Number Title Principal Investigator
A021502 NCT02912559 Randomized Trial of Standard Chemotherapy alone or combined with Atezolizumab as adjuvant therapy for patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair(ATOMIC: Adjuvant Trial of Deficient Mismatch Repair in Colon Cancer) David Chism, MD
NRG-GI005 NCT04068103

Phase II/III Study of Circulating tumor DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)

 

David Chism, MD

EA2176 NCT04444921

 

A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients

David Chism, MD


Genitourinary

Protocol Number NCT Number Title Principal Investigator
NRG-GU009 NCT04513717 Parallel Phase III Randomized Trials for High Risk Prostate Cancer evaluating De-Intensification for Lower Genomic risk and intensification of concurrent therapy for Higher Genomic risk with radiation (PREDICT-RT*) *Prostate RNA Expression/Decipher to Individualize Concurrent Therapy with Radiation David Chism, MD
IMMU-132-06

NCT03547973

A Phase II Open-Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy

David Chism, MD

Gynecologic 

Protocol Number NCT Number Title Principal Investigator
NRG-GY023  NCT04739800 A Randomized Phase II Trial of Triplet Therapy (a PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination with Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women with Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab Brook Saunders, MD

Head and Neck 

Protocol Number NCT Number Title Principal Investigator
EA3202 NCT05063552 A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers David Chism, MD

Leukemia/Lymphoma

Protocol Number NCT Number Title Principal Investigator
AZA-MDS-006 (CONNECT) NCT01688011  The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry David Chism, MD
NDS-DLBCL-003
NCT04982471

Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study

David Chism, MD

 

M22-132 NCT05283720

Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin Lymphoma

David Chism, MD

 


Lung: Non-Small Cell

Protocol Number NCT Number Title Principal Investigator
BX43361 NCT054191375 Master screening study to determine biomarker status and potential trial eligibility for patients with malignant tumors David Chism, MD
BO42777 NCT05170204 A phase i-iii, multicenter study evaluating the efficacy and safety of multiple therapies in cohorts of patients selected according to biomarker status, with locally advanced, unresectable, stage iii non-small cell lung cancer David Chism, MD

M14-239

NCT03539536

Phase II, Open-Label Safety and Efficacy Study of Telisotuzuumab Vedotin (ABBV-399) in Subjects with previously Treated c-Met+ NSCLC  Non-Squamous

David Chism, MD

NIT-119

NCT04984811

Phase II study to evaluate anti-tumor efficacy and safety of NT-I7 (efineptakin alfa) in combination with atezolizumab in subjects with previously untreated, PD-L1-expressing, locally advanced or metastatic Non-Small Cell LunA multicenter, open-label, single-arg Cancer

David Chism, MD

Melanoma

Protocol Number NCT Number Title Principal Investigator
EA6141 NCT02339571 Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma David Chism, MD

Pancreatic

Protocol Number NCT Number Title Principal Investigator
EA2186 (GIANT) NCT04233866 A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT) David Chism, MD

Clinical Trial Studies – COMING SOON! 



Protocol Number NCT Number Title Principal Investigator
BO42592 (Skyscraper 06)

NCT04619797

A PHASE II/III, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF TIRAGOLUMAB IN COMBINATION WITH ATEZOLIZUMAB PLUS PEMETREXED AND CARBOPLATIN/CISPLATIN VERSUS PEMBROLIZUMAB PLUS PEMETREXED AND CARBOPLATIN/CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER

David Chism, MD




Protocol Number NCT Number Title Principal Investigator
BO43936 (Skyscraper 10)   A Randomized Open Label Phase II Study of Immune Checkpoint Combinations with Axitinib in Patients with Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma David Chism, MD